New hope for lung cancer patients with brain tumors
NCT ID NCT06970639
Summary
This international Phase 3 trial is testing whether a new drug, furmonertinib, works better when combined with standard chemotherapy compared to the current standard drug, osimertinib, for patients with a specific type of lung cancer that has spread to the brain. The study aims to see if the combination can better control the cancer and improve survival. It will enroll about 380 adults with non-small cell lung cancer who have not yet received treatment for their advanced disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC PATIENTS WITH BRAIN METASTASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Provincial People's Hospital
RECRUITINGGuangdong, Guangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.